Forward Foods introduces Detour Lean Muscle bar
MINDEN, Nev. Forward Foods, maker of Detour, on Wednesday announced the addition of the Detour Lean Muscle bar to its existing line of energy bars.
With 32 grams of high-quality protein and only 3 grams of sugar, Detour Lean Muscle is designed to help serious athletes build and maintain lean muscle mass. Detour Lean Muscle is fortified with 20 vitamins and minerals and provides 2,000 mg of omega 3’s per bar, a first in the protein bar category according to the company.
“Our consumer research shows that many serious athletes consider building lean muscle mass to be the next level of physical achievement, and they’re looking for a protein bar to help them reach that goal,” stated Patrick Muldoon, chief executive officer of Forward Foods. “The Detour brand is known for providing high performance protein and great taste, so a premium bar that also provides vitamins, minerals and healthy fats should really connect with consumers and is a great addition to the Detour product line.”
Detour Lean Muscle will be initially available in cookie dough caramel crisp flavor. Each bar contains 350 calories. The bars will be available in health and fitness retailers and online at www.detourbar.com in September.
MacKay tapped as regulatory and scientific affairs VP for CRN
WASHINGTON The Council for Responsible Nutrition on Tuesday named Douglas (Duffy) MacKay to the post of vice president for regulatory and scientific affairs.
“We are extremely excited to welcome Dr. MacKay to our staff,” stated Steve Mister, CRN president and chief executive officer. “As a licensed naturopathic doctor, he adds an impressive combination of theoretical and practical expertise to our scientific team.”
Prior to joining CRN, MacKay served as vice president, clinical research, for Nordic Naturals, where during his four years with the company he was responsible for product formulation, coordinating clinical trial research, serving as technical/medical advisor, and managing the firm’s Adverse Event Reporting system, among other duties. MacKay also previously served as a senior technical advisor for Thorne Research and senior editor of the peer-reviewed clinical journal, Alternative Medicine Review. In addition, for seven years he was a co-owner and doctor in a complementary and alternative private practice, the Makai Naturopathic Center in New Hampshire.
MacKay will serve as CRN’s resident expert on botanicals, the association stated.
NSAIDs lower protien used in prostate cancer test
WASHINGTON Use of such nonsteroidal, anti-inflammatory drugs as ibuprofen or aspirin lowers the levels of a protein that doctors use to screen for prostate cancer, according to a report published in the medical journal Cancer, a Reuters report stated Monday.
However, it is unclear as to whether this means men taking an NSAID have a lower risk of developing potential prostate cancer, or if it simply means NSAIDs make it more difficult to identify prostate cancer in its early stages, the researchers concluded.